Where Do Novel Drugs of 2016 Fit In?
Total Page:16
File Type:pdf, Size:1020Kb
FORMULARY JEOPARDY: WHERE DO NOVEL DRUGS OF 2016 FIT IN? Maabo Kludze, PharmD, MBA, CDE, BCPS, Associate Director Elizabeth A. Shlom, PharmD, BCPS, SVP & Director Clinical Pharmacy Program Acurity, Inc. Privileged and Confidential August 15, 2017 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ◆ Identify orphan drugs and first-in-class medications approved by the FDA in 2016. ◆ Describe the role of new agents approved for use in oncology patients. ◆ Identify and discuss the role of novel monoclonal antibodies. ◆ Discuss at least two new medications that address public health concerns. Neither Dr. Kludze nor Dr. Shlom have any conflicts of interest in regards to this presentation. Privileged and Confidential 2016 NDA Approvals (NMEs/BLAs) ◆ Nuplazid (primavanserin) P ◆ Adlyxin (lixisenatide) ◆ Ocaliva (obeticholic acid) P, O ◆ Anthim (obitoxaximab) O ◆ Rubraca (rucaparib camsylate) P, O ◆ Axumin (fluciclovive F18) P ◆ Spinraza (nusinersen sodium) P, O ◆ Briviact (brivaracetam) ◆ Taltz (ixekizumab) ◆ Cinqair (reslizumab) ◆ Tecentriq (atezolizumab) P ◆ Defitelio (defibrotide sodium) P, O ◆ Venclexta (venetoclax) P, O ◆ Epclusa (sofosburvir and velpatasvir) P ◆ Xiidra (lifitigrast) P ◆ Eucrisa (crisaborole) ◆ Zepatier (elbasvir and grazoprevir) P ◆ Exondys 51 (eteplirsen) P, O ◆ Zinbyrta (daclizumab) ◆ Lartruvo (olaratumab) P, O ◆ Zinplava (bezlotoxumab) P ◆ NETSTPOT (gallium Ga 68 dotatate) P, O O = Orphan; P = Priority Review; Red = BLA Privileged and Confidential History of FDA Approvals Privileged and Confidential Orphan Drugs ◆FDA Office of Orphan Products Development • Orphan Drug Act (1983) – drugs and biologics . “intended for safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug.” . Incentives to pharmaceutical manufacturers: o Federal funding for clinical trials o Tax credit – 50% of clinical testing costs o 7 years market exclusivity from date of approval o FDA approval via priority status (6 vs 10 month approval; fee waived) • 7000 rare diseases affecting 25-30 million people in U.S. www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ucm2005525.htm Privileged and Confidential Orphan Drugs ◆Orphan Drug Approvals • Average of 8 Orphan drugs approved per year • 349 Orphan drugs approved 1983-2009 . Rising rate of approvals: 33% (1983-2005), 37% (2009-2015), 47% (2015) . 65% are NME vs. 35% are BLA • Drug categories . 28% oncology . 15% infectious diseases (including HIV) . 11% neurological/psychiatric . 10% enzyme deficiencies • Increasing Orphan drugs targeting biomarker-defined disease subsets (e.g. ALK+ NSCLC, BRAF V600E met melanoma) Kesselheim AS. Innovation and the Orphan Drug Act, 1983-2009: Regulatory and Clinical Characteristics of Approved Orphan Drugs. Kesselheim AS, Treasure CL, Joffe S. Biomarker-defined subsets of common diseases:: Policy and economic mplications of orphan drug act coverage. PLoS Med 2017;14(1):e1002190. Privileged and Confidential Hepatobiliary Diseases ◆Defitelio® (defibrotide sodium) ◆Epclusa® (sofosbuvir and velpatasvir) ◆Zepatier® (elbasvir and grazoprevir) ◆Ocaliva® (obeticholic acid) Privileged and Confidential Defitelio® (defibrotide) by Jazz Pharmaceuticals ◆ Indication1: treatment of hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction after hematopoietic stem-cell transplantation (HSCT) in adults and pediatric patients ◆ Veno-occlusive disease (VOD)/SOS2 • Occurs when damaged endothelial cells are torn away from the sinusoid leading to fibrin deposition and evenutally red blood cells entering the space are blocked in very small blood vessels within the liver • Incidence rate is estimated to be approximately 10–15% and occurs within 20–30 days of the transplant • Untreated hepatic VOD/SOS accompanied by multi-organ failure (MOF) is associated with >80% mortality ◆ Mechanism of action2 • Oligonucleotide mixture with profibrinolytic properties • Promotes the breakdown of fibrin and protects endothelial cells from harmful effects of chemotherapy • Posseses anti-inflammatory, anti-ischemic, antithrombotic, and thrombolytic properties 1. Defitelio®[prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals. March 2016 2. Stein C et a. Mol Ther Nucleic Acids. 2016 Aug; 5(8): e346. 2016 Aug; 5(8): e346. Privileged and Confidential Defitelio® (defibrotide) by Jazz Pharmaceuticals ◆ Dose1 • 6.25 mg/kg every 6 hours • Use weight prior to the preparative regimen for HSCT to calculate dose ◆ Administration1 • Infuse over 2 hours using a 0.2 micron in-line filter • Administer for a minimum of 21 days and until the signs and symptoms of VOD have resolved or up to a maximum of 60 days • Must be used within 4 hours if stored at room temperature or within 24 hours if stored under refrigeration ◆ Safety • ADE's (incidence ≥10%): Hypotension, diarrhea, vomiting, nausea and epistaxis, • Serious ADRs: Hypotension (11%) and pulmonary alveolar hemorrhage (7%) ◆ Ordering2 • Verify your institution has a contract with McKesson Plasma and Biologics before ordering ◆ Contraindications1 • Antithrombotic agents 1.Defitelio®[prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals. March 2016; 2. https://defitelio.com/ Privileged and Confidential Defitelio® (defibrotide) by Jazz Pharmaceuticals Study Design N Dose & Administration % Survived after 100 days of transplantation Study 1 prospective study, patients had a diagnosis of 102 6.25 mg/kg every 6 hours for a minimum 38% Day +100 survival after VOD with an associated diagnosis of multi- of 21 days until discharge from hospital transplantation organ dysfunction (pulmonary, renal, or both) by Day+28 post-HSCT Study 2 prospective study, diagnosis of hepatic VOD 75 6.25 mg/kg infused every 6 hours for a 44% Day +100 survival after and multi-organ dysfunction following HSCT minimum of treatment duration of 14 days transplantation Study 3 expanded access program for defibrotide for 351 6.25 mg/kg infused every 6 hours 45% Day +100 survival after the treatment of adult and pediatric patients transplantation who developed hepatic VOD after had received a HSCT and developed hepatic VOD with renal or pulmonary dysfunction. Privileged and Confidential Epclusa® (sofosbuvir/velpatasvir) by Gilead Sciences ◆ First completely oral pan-genotypic single tablet regimen for the treatment hepatitis C virus (HCV) infection ◆ Indication • Treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection • Can be use in patients co-infected with HIV (expanded labeling August 2017) ◆ Potential to eliminate genotype testing ◆ Direct-acting antiviral agent ◆ NS5B polymerase inhibitor (sofosbuvir) and NS5A inhibitor (velpatasvir) ◆ Dose/Administration • Fixed-dose combination of sofosbuvir 400 mg/ velpatasvir 100 mg once daily for 12 weeks • Single tablet for patients without cirrhosis or with compensated cirrhosis • In combination with ribavirin for decompensated cirrhosis Epclusa®[prescribing information]. Foster City, CA: Gilead Sciences. February 2017 Privileged and Confidential Zepatier® (elbasvir/grazoprevir) by Merck Sharp & Dohme Zepatier Dosage Regimens and Durations ◆ Indication Genotype Patient Population Therapy Duration • Treatment of hepatitis C genotypes 1 or 4 infection in adults with 1a Treatment-naïve or Zepatier alone 12 weeks or without ribavirin PegIFN/RBV ◆ Direct-acting antiviral agent experienced* without baseline NS5A ◆ Oral fixed-dose combination of a NS5A inhibitor polymorphisms† (elbasvir) and a NS3/4A protease inhibitor 1a Treatment-naïve or Zepatier plus 16 weeks (grazoprevir) PegIFN/RBV- ribavirin ◆ Safety experienced* with • Zepatier alone: fatigue, headache, nausea baseline NS5A • Zepatier with ribavirin: anemia and headache polymorphisms† ◆ Dosage 1b Treatment-naïve or Zepatier alone 12 weeks • Elbasvir 50 mg /grazoprevir 100 mg once daily PegIFN/RBV • Renal impairment experienced* . No dosage adjustments including dialysis 1a or 1b PegIFN/RBV/PI- Zepatier plus 12 weeks • Hepatic Impairment experienced‡ ribavirin . No adjustment in mild impairment 4 Treatment-naïve Zepatier alone 12 weeks . Contraindicated in moderate or severe impairment 4 PegIFN/RBV- Zepatier plus 16 weeks experienced* ribavirin *Peginterferon alfa (PegIFN) + ribavirin (RBV) †Polymorphisms at amino acid positions 28, 30, 31, or 93. Zepatier®[prescribing information]. Whitehouse, NJ: Merch Sh.arp & Dohme Corp. February 2017 ‡Peginterferon alfa + ribavirin + HCV NS3/4A protease inhibitor. Privileged and Confidential Approval History of Direct-Acting Antiviral Agents for HCV WARNING: Risk of hepatitis B reactivation in patients coinfected with HCV and HBV Daklinza® Zepatier® (elbasvirsvir/grazoprevir) Sovaldi® (daclatasvir) Genotype: 1, 4 (sofosbuvir) Genotype: 3 Approval: Jan 2016 Genotype: 1, 2, 3, 4 Approval: Jul 2015 Approval: Dec 2013 Viekira Pak ® Genotype: 1 Approval: Dec 2014 2013 2014 2015 2016 Harvoni® Olysio® Eplcusa® (ledipasvir/sofosbuvir) (simeprevir) (sofosbuvir /velpatasvir) Genotype: 1, 4, 5, 6 Genotype 1 Genotype: 1, 2, 3, 4, 5, or 6 Approval: Nov 2015 Approval: Nov 2014 Approval: June 2016 Privileged and Confidential Ocaliva® (obeticholic acid) by Intercept Pharmaceuticals ◆ Indication • For the treatment of primary biliary cholangitis (PBC) in